Pithomyces chartarum Allergy Shots: The Veterinary Mycotoxin Story Behind Your Panel Positive
Pithomyces chartarum is better known in veterinary medicine for sporidesmin mycotoxin causing facial eczema in grazing sheep than in human allergy clinics. No WHO/IUIS-registered Pithomyces allergens exist, and no SCIT-specific RCT has been published. A positive Pithomyces result is interpreted within the Pleosporales family framework — with Alternaria evidence (Kuna 2011, Tabar 2019) as the operative SCIT anchor.
Pithomyces chartarum Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to pithomyces chartarum — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of pithomyces chartarum allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of pithomyces chartarum immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of pithomyces chartarum extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for pithomyces chartarum allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing pithomyces chartarum extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription pithomyces chartarum immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat pithomyces chartarum allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Pithomyces chartarum?
The biology, taxonomy, and clinical fingerprint of Pithomyces chartarum — the foundation of how SCIT targets it.
Pithomyces chartarum produces distinctive multicellular dictyoseptate conidia that are readily aerosolized from dead grass — a common feature of late-summer pastoral and temperate environments.
- Scientific name
- Pithomyces chartarum
- Family
- DidymosphaeriaceaePleosporales order
- Type
- Outdoor dematiaceous saprophyte on dead grass
- Native to
- Temperate and subtropical regions worldwide; major economic threat in New Zealand and Australian pastoral farming
- Allergen proteins
- No WHO/IUIS-registered Pithomyces allergens as of 2024Order-level Pleosporales cross-reactivity via enolase, MnSOD, serine protease pan-fungal allergens (Crameri 2014)
- Particle size
- Dictyoseptate conidia 18-29 x 10-17 µm
- Avoidance difficulty
- Very difficult
How Pithomyces chartarum Allergy Presents
Symptoms by body system — useful for distinguishing Pithomyces chartarum sensitivity from overlapping allergies and infections.
Respiratory
- Seasonal allergic rhinitis during late-summer spore peaks
- Asthma exacerbations in sensitized individuals on high-count outdoor days
- Sneezing and nasal congestion with outdoor exposure in late summer and fall
- Cough triggered by aerosolized spores from dead grass
Ocular
- Itchy watery eyes during high outdoor mold counts
- Conjunctival redness in sensitized individuals
- Periorbital swelling during peak season
Dermal
- Atopic dermatitis flares in late summer-fall among sensitized patients
- Non-specific pruritus during high-spore periods
- Skin irritation from contact with contaminated organic material
Systemic
- Fatigue from chronic exposure during peak mold season
- Sleep disruption secondary to nasal congestion
- Reduced outdoor tolerance during high-count late-summer afternoons
- Malaise in patients with poorly controlled mold allergy
When I see Pithomyces on a panel, the first question I ask is whether there is co-sensitization to Alternaria — because that is where the therapeutic decision lives. Pithomyces is on the panel for aerobiologic completeness, not because we have Pithomyces-specific immunotherapy. A positive result that changes management almost always does so by confirming the Pleosporales sensitization pattern that warrants Alternaria-based SCIT.
When & Where Pithomyces chartarum Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late summer through early autumn, paralleling Alternaria and other Pleosporales saprophyte peaks· Approximately 10-14 weeks of meaningful outdoor spore loads in temperate regions
US Exposure Map
3 high-intensity statesWhat Pithomyces chartarum Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Pithomyces chartarum shares order-level Pleosporales cross-reactivity with Alternaria and related dematiaceous fungi via pan-fungal allergens including enolase, manganese superoxide dismutase, and serine proteases (Crameri 2014). No species-specific Pithomyces allergen has been characterized.
Order-level Pleosporales cross-reactivity via pan-fungal proteins; Alternaria carries the SCIT evidence (Kuna 2011)
Didymosphaeriaceae family member with better-characterized allergens and stronger sensitization data
Is SCIT Right for Your Pithomyces chartarum Allergy?
Answer five questions to evaluate whether your mold sensitization pattern — including a Pithomyces positive — warrants an allergist evaluation for Pleosporales SCIT.
How severe are your late-summer outdoor mold allergy symptoms?
The Pithomyces chartarum SCIT Protocol
When Pithomyces sensitization is part of a broader Pleosporales mold sensitization pattern warranting SCIT, therapy is administered as Alternaria-based extract — no Pithomyces-specific vial exists in clinical practice. Mold SCIT requires a separate vial from pollen extracts.
Weekly escalating doses of non-standardized Alternaria extract. With Curex, the prescribing physician supervises the first dose and every dose change live over Zoom and confirms a prescribed epinephrine auto-injector on hand. Pre-injection peak flow measurement is recommended given the Pleosporales-asthma severity association.
Once the target dose is reached, maintenance injections continue monthly or every 2-4 weeks. Your allergist will monitor local reaction size and clinical response to guide dose adjustments.
After 3-5 years of successful maintenance, the allergist evaluates lasting tolerance and whether continuation beyond 5 years is clinically appropriate.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Pithomyces chartarum SCIT
No published SCIT RCT exists for Pithomyces chartarum. SCIT decisions extrapolate from Alternaria DBPC-RCTs on the basis of shared Pleosporales order membership and pan-fungal allergen cross-reactivity.
- Alternaria SCIT: Combined symptom-medication score reduction (year 3)63%Kuna et al., J Allergy Clin Immunol 2011, N=111 children, DBPC-RCT
- Alternaria SCIT: Efficacy after 1 year with native Alt a 140%Tabar et al., J Allergy Clin Immunol 2019, purified Alt a 1 DBPC-RCT
No published SCIT trial isolates Pithomyces chartarum as the immunizing antigen. No WHO/IUIS allergens are registered for this species. SCIT decisions for patients with Pithomyces sensitization extrapolate from the Alternaria DBPC-RCT evidence (Kuna 2011: 63.5% combined score reduction) and the Pleosporales order-level evidence framework. A board-certified allergist should confirm whether primary Pleosporales sensitization is present before applying this evidence to any individual patient.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Pithomyces chartarum SCIT Side Effects
Side effects of Alternaria-based mold SCIT (the practical treatment approach when Pithomyces is in a Pleosporales sensitization pattern) follow standard SCIT safety parameters, with somewhat higher local reaction rates for mold than pollen extracts.
Local reactions
4 documentedSystemic reactions
4 documentedSystemic reactions, when they occur, typically begin within about 30 minutes of an injection. With Curex at-home mold SCIT, the prescribing physician supervises the first dose and every dose change live over Zoom and confirms a prescribed epinephrine auto-injector on hand before the first injection. Patients with active asthma require pre-injection peak flow measurement.
SCIT vs Alternatives for Pithomyces chartarum
Patients with Pithomyces and Pleosporales sensitization can consider Alternaria-based SCIT, at-home SLIT drops, environmental controls, or daily pharmacotherapy for mold allergy management.
| Criterion | At-Home SCIT (Curex, Alternaria-based)Best | SLIT drops | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | 63% combined score reduction (Kuna 2011) for Pleosporales | Alternaria SLIT data emerging; mold mix SLIT not established | Partial — outdoor mold avoidance is difficult | Symptomatic relief only |
| 5-yr cost | $3,500-$8,000 over 5 years | $500-$2,000/yr | HEPA filters $100-$500/yr | $500-$2,000/yr ongoing |
| Duration | 3-5 years | 3-5 years | Ongoing | Ongoing daily use |
| Convenience | At-home self-injection; weekly then monthly | Daily at-home drops | Lifestyle modification required | Daily pills/sprays |
| Safety | Systemic reactions <1%; Zoom-supervised dosing + prescribed epi | Lower systemic reaction risk | No injection risk | Drug side effects with long-term use |
| Lasting effect | Yes — tolerance may persist after treatment | Evidence less robust than SCIT for molds | No lasting desensitization effect | No lasting effect |
At-Home SCIT (Curex, Alternaria-based)Best
SLIT drops
Avoidance
Medications
Alternaria-based SCIT is the best-evidenced immunotherapy for Pleosporales mold sensitization, including Pithomyces. Curex now delivers that SCIT as an at-home allergy shot at $129/month: an Alternaria-based serum compounded under USP <797>, with the first dose and every dose change supervised live over Zoom, a prescribed epinephrine auto-injector confirmed on hand, and allergist-overseen escalation — discuss with your allergist to determine the right fit for your symptom profile.
What Pithomyces chartarum SCIT Actually Costs
Curex at-home testing covers extended mold panels including dematiaceous fungi like Pithomyces, helping rural and agricultural patients map their full sensitization profile. Most major insurers cover mold SCIT when ordered by a board-certified allergist; verify your specific plan's allergy benefit and deductible.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your pithomyces chartarum allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Pithomyces chartarum SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Pithomyces chartarum appears on extended mold panels because it is an aerobiologically common dematiaceous fungus detected regularly in outdoor spore counts, particularly in temperate and subtropical regions during late summer. Its inclusion on panels from Greer, Hollister-Stier, and others represents aerobiological thoroughness rather than a dedicated therapeutic target. A positive Pithomyces result is clinically meaningful for two reasons: it confirms Pleosporales sensitization (a relevant allergy-risk cluster), and it prompts evaluation for co-sensitization to Alternaria — which does have SCIT RCT evidence. The test result is informative for risk stratification even when it does not add a new treatment option.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.